SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a Bitcoin-native meme coin launched via the Runes protocol, is trending as the community rallies around its fair distribution and potential to drive utility on the Bitcoin network.  Many see it as a cultural movement and are actively discussing its unique position compared to other meme coins like $DOGE.X. Some community members also highlight the accumulation of $DOG.X by a publicly listed company.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the board considers a large compensation package for Musk tied to ambitious AI and robotaxi goals, sparking debate about the company's future and Musk's performance. The community is discussing the feasibility of these targets and the potential impact on the stock, with some questioning Tesla's valuation and competitive position, especially against Chinese EV manufacturers. Recent news around Robotaxi and a Tesla Megapack project are also adding to the conversation.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

$SNAP is trending as traders buzz about potential AI integration and buyout rumors, with some pointing to activity on WallStreetBets and X as a potential catalyst. Community members are actively speculating on potential acquirers and comparing valuations to competitors like Reddit. Technical analysis and short squeeze potential are also being discussed.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid speculation of a potential acquisition or strategic partnership following a recent CEO transition and board shake-up. Fueling the discussion is a rumor of a Nestle buyout offer, leading to community debate about its validity and the potential impact on shareholder value. With high short interest, many anticipate a possible short squeeze if positive news emerges, while others express caution due to the company's history.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending as traders debate its next move amid fluctuating natural gas prices and storage levels. Community discussions revolve around technical analysis, potential bullish or bearish signals, and the impact of weather forecasts on demand. Some traders anticipate a rebound, while others foresee further declines, creating a mixed sentiment around BOIL's short-term prospects.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

The crypto community is buzzing about $DOG, a new meme coin on the Bitcoin network, celebrated for its fair launch and community-driven approach. Many see it as the premier meme coin for Bitcoin, drawing comparisons to $SHIB's role on Ethereum and predicting it will overtake $DOGE. Community members are drawn to its organic growth, lack of insider allocation, and strong support base, with some anticipating listings on major exchanges.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending as investors anticipate the impact of a recently announced large government contract with Germany and other potential deals, while monitoring upcoming earnings. The community is buzzing about the company's decision to announce earnings from the floor of the NYSE, speculating it signals major news, possibly a crazy good earnings beat, positive guidance, or even a buyout, and assessing the potential for a breakout above key resistance levels. With institutional ownership increasing, attention is turning towards Planet Labs' growth potential within the broader space and defense technology sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid speculation about its potential inclusion in the S&P 500, with the official announcement expected soon, generating significant buzz among investors. The community is actively discussing potential price targets and the impact of index fund inflows, with some comparing it to past inclusion events of other high-growth stocks. Some traders are positioning for a potential short squeeze while others are taking profits, as well as discussing the upcoming Robinhood Summit.

American Bitcoin Corp. is a bitcoin accumulation platform focused on building America's bitcoin infrastructure platform. It delivers institutional-grade exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded on October 22, 2020 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. ($ABTC) is trending due to its recent NASDAQ debut and ties to the Trump family (Eric Trump), sparking significant retail interest. Community members are actively discussing the stock's potential as a Bitcoin play and its low float, while others are wary of dilution risks and the company's valuation. Bullish sentiment is fueled by potential short squeeze setups, while bearish arguments focus on market cap and asset valuation relative to Bitcoin holdings.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending as retail investors rally behind potential catalysts like a new CEO announcement and speculation around future interest rate cuts. Community members are actively discussing potential gamma squeezes, the influence of activist investor Eric Jackson, and celebrity endorsements. Some are drawing comparisons to past meme stock rallies, while others express concern about the company's fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit US equity futures are slightly higher , hovering near all time highs as traders bet that data on Friday will bolster the case for interest rate...

Precigen, Inc. (PGEN) said on Friday that the US Food and Drug Administration (FDA) has approved its immunotherapy Papzimeos for the treatment of adults with recurrent respiratory papillomatosis (RRP).Recurrent respiratory papillomatosis (RRP) is a rare condition where benign, wart-like tumors, called papillomas, grow in the respiratory tract, most commonly the larynx or the voice box. The disease can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. According to Precigen, there are about 27,000 adult RRP patients in the U.S.Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with RRP, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/precigen-announces-full-fda-approval-of-papzimeos-zopapogene-imadenovec-drba-the-first-and-only-approved-therapy-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-302530957.html">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PGEN">Precigen</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 50% higher in the pre-market session at the time of writing.“With the landmark FDA approval of Papzimeos and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," said CEO Helen Sabzevari. Management of RRP, the company said, previously primarily consisted of repeated surgeries that did not address its root cause.The FDA approval was supported by data from an open-label, single-arm study in adult patients with RRP in which 51% of study patients required no surgeries in the 12 months after treatment with Papzimeos. Further, the therapy was well-tolerated in the trial with no serious treatment-related adverse events.Precigen noted that no confirmatory clinical trial is required for the therapy, which is delivered via four subcutaneous injections over a 12-week interval. The company added that it will begin promoting Pazimeos immediately.H.C. Wainwright subsequently raised its price target on Precigen to $8.50 from $6 while keeping a 'Buy' rating on the shares. The firm expects the drug to generate sales of $1.1 billion in 2033 from $138 million in 2026.PGEN stock is up by 65% this year and by about 73% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-climbs-premarket-even-after-warren-buffett-s-berkshire-trims-stake/chsPjsBRdf9">Apple Stock Climbs Premarket Even After Warren Buffett’s Berkshire Trims Stake</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why

The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. 

Equity

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 FDA Grants...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN...

Small-cap, clinical-stage biopharma Precigen, Inc. ($PGEN) rallied on Monday following a regulatory update. The stock ended the session 28.47% higher at $0.9331 on more than six times the average volume.Germantown, Maryland-based Precigen announced the completion of the rolling submission for a biologic license application (BLA) for PRGN-2012, a gene therapy being investigated as a treatment option for adult patients with recurrent respiratory papillomatosis (RRP).RRP is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx, and it is caused by the human papillomavirus (HPV) 6 or HPV 11. It can prove fatal.&nbsp;Precigen said the BLA is now in the initial 60-day review period and the FDA will decide whether to accept the application for further review and set the Prescription Drug User Fee Act (PDUFA) date by this period.The company also noted that the application included a request for priority review, which, if granted, will reduce the review period from 10 months to six months.PRGN-2012 acts by eliciting immune responses directed against cells infected with HPV 6 or HPV 11. The company noted that there is no cure for the condition currently and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease.&nbsp;The regulatory application is supported by pivotal Phase 1/2 study results, which showed more than 50% of patients achieved complete response and more than 85% had a decrease in surgical interventions the year after the treatment.&nbsp;Helen Sabzevari, President and CEO of Precigen, "We look forward to working closely with the FDA on next steps now that we have completed the BLA submission and we are excited by the potential to bring PRGN-2012 to RRP patients as quickly as possible."'The executive also said, with the recent $79 million private placement of convertible preferred stock, the company has extended its cash runway into 2026, well beyond the potential commercial launch in the second half of 2025.<figure class="image"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pgen_sentiment_0fbe6731dd.png" alt="pgen-sentiment.png" width="637" height="135"><figcaption>PGEN sentiment and message volume December 31, 2024, as of 3:36 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Precigen flipped from ‘extremely bearish’ a day ago to ‘extremely bullish’ (96/100), the highest in a year. Message volume also spurted from ‘normal’ to ‘extremely high.’In a message posted on the PGEN stream on Stocktwits, a user said they looked ahead to a good 2025 for the company.&nbsp;<stembedurl>https://stocktwits.com/ASTAD13/message/598217372</stembedurl>If the company manages to get a priority voucher, it can resell it for $100 million, another noted.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/598207700</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/analyst-picks-pegasystems-stock-among-top-10-tech-winners-of-2025/cJO1z97Rkm">Analyst Picks Pegasystems Stock Among Predicted Top 10 Tech Winners Of 2025: Retail Shares The Optimism</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis Precigen Completes Submission of...

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock PR Newswire...

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.09	--	--	N/A
Q2 '25	-$0.09	--	--	N/A
Q1 '25	-$0.18	-$0.18	--	EXPECTED
Q4 '24	-$0.05	-$0.07	-40.35%	MISSED
Q3 '24	-$0.09	-$0.09	-4.34%	MISSED

PGEN
Precigen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest PGEN News

PGEN Precigen Inc